A comprehensive review of treatment options for patients with metastatic hormone-sensitive prostate cancer. Alicia Morgans, M.D., MPH: Metastatic hormone-sensitive prostate cancer is a particular type ...
Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...
The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) delivered mixed recommendations for ...
MedPage Today on MSN
FDA panel endorses broader capivasertib use in prostate cancer
Agency staff expressed uncertainty over whether PFS benefit was "clinically meaningful" ...
TLX597-Tx is a PSMA1-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Let me introduce ...
US FDA’s ODA committee recommends approval of AstraZeneca’s Truqap for PTEN-deficient metastatic hormone-sensitive prostate cancer: Cambridge, UK Monday, May 4, 2026, 17:00 Hr ...
Mark Stein, MD, explores managing mHSPC through PSMA PET imaging, tumor burden assessment, and AMPLITUDE trial data while considering clinical context. The widespread adoption of PSMA PET imaging has ...
Akeega reduced radiographic progression or death risk by 37% in mCSPC patients with HRR gene alterations. Significant reduction in symptomatic progression risk by 50% and a trend towards improved ...
Please provide your email address to receive an email when new articles are posted on . Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results